Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations

v3.26.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Other revenue $ 1,404 $ 0
Operating expenses    
Research and development 1,037 6,645
General and administrative 3,653 4,638
Gain on sale of Baergic (203) 0
Total operating expenses (4,487) (11,283)
Loss from operations (3,083) (11,283)
Interest income (121) (176)
Loss on common stock warrant liabilities 0 759
Change in fair value of warrant liability (15) (170)
Net loss (2,947) (11,696)
Net loss attributable to non-controlling interest (38) (44)
Net loss attributable to common stockholders $ (2,909) $ (11,652)
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share) $ (0.93) $ (15.79)
Weighted average number of common shares outstanding, basic and diluted (in shares) 3,131,131 1,295,207